Despite the widespread use of cART, cognitive impairment continues to be a prevalent concern in both symptomatic and asymptomatic individuals with chronic HIV infection.1 The relationship between sleep and cognitive performance assessed by comprehensive neuropsychological and sleep function evaluation in an HIV cohort has not been previously reported. Our results suggest that both subjective and objective indices of sleep continuity and quality may have a significant relationship with cognitive performance in HIV-positive individuals.
Furthermore, many participants demonstrated patterns strongly suggestive of chronic partial sleep deprivation, which may be the result of behaviorally induced insufficient sleep syndrome.42 According to the International Classification of Sleep Disorders-2 classification, the key diagnostic features of this syndrome refer to an individual who reports customary sleep times (at home during their “normal routine”) measured by history, sleep diary, or actigraphy which is significantly shorter than the sleep time recorded when placed in a noncustomary setting (eg, PSG in sleep research facility). Due to this self-imposed chronic partial sleep debt, when the individual is provided an ad libitum sleep opportunity in a research facility (despite the unfamiliar environment and cumbersome recording techniques), he or she will often show “supra” efficient sleep architectural patterns, including very high sleep efficiency, markedly short sleep onset latency, and minimal sleep fragmentation on PSG. Similar to the patterns characterized by those with behaviorally induced insufficient sleep syndrome, many of the individuals in our cohort demonstrated markedly reduced sleep latencies of <10 minutes with sleep efficiencies often greater than 90% on their PSGs. In turn, many of these same participants demonstrated significantly shorter sleep durations on their 2-week home monitoring compared with their PSG and much shorter durations than the recommended 7.5–8.5 hours needed for most adults to function optimally. Study participants demonstrating patterns suggestive of chronic partial sleep deprivation reported more complaints of daytime sleepiness and performed significantly poorer on several measures of cognitive function compared with participants without these suggestive patterns.
Interestingly, self-reported daytime sleepiness, based on the ESS, was significantly higher in the cognitively unimpaired group (using Frascati criteria) than in the impaired group. The ESS inquires about the likelihood of “dozing” in specific scenarios, such as while in a movie theatre or meeting or while driving. Because most of our cohort was not actively employed and did not own an automobile, these scenarios may not have occurred customarily enough for our cohort to accurately respond. Based on our findings, future studies evaluating the relationship between sleep and cognition amongst HIV-positive individuals should consider the participant’s historical sleep behaviors, attitudes, daily habits, and relevant sociodemographic factors (ie, employment and residential status, common means of transportation).
Some studies have suggested that demographics, such as female gender, age, low body mass index, and history of intravenous drug use, may increase the risk for future cognitive impairment in seropositive individuals. Overall, health status may also be a potential issue, with 2 large longitudinal cohort studies (the Central Nervous System HIV Antiretroviral Therapy Effects Research and MACS) reporting increased risk for HAND development in aviremic subjects who suffered with “incidental” comorbidities (examples include low reading level, school problems, brain trauma, history of cerebrovascular events, epilepsy, central nervous system opportunistic diseases, major depression, psychotic disorder, and substance abuse) compared with aviremic participants without these comorbidities.1,3
Although this study yielded several important findings, its ability to detect subtle cognitive differences based on a 4-tiered Frascati classification may have been limited by its relatively small sample size. Conducting this type of study utilizing multimethod sleep assessments and observations across several time points requires an inordinate amount of financial and personnel resources. Even though our study sample of predominantly black males may place limits on generalizability, CDC statistics continue to show that black males are disproportionately affected by HIV as compared with other demographic groups.53 Significantly lower mean sleep durations have also been reported for black men compared with other demographic groups in general population studies,53 and similar sleep behavioral patterns suggestive of self-imposed chronic partial sleep deprivation were also revealed in our cohort. Providing counseling on the importance of adequate sleep opportunity may prove to be an effective health care management strategy. Although HIV-positive individuals undergoing treatment with efavirenz were excluded in this study to minimize confounding medication-related effects on sleep,54,55 evidence regarding the impact of efavirenz on sleep is mixed with some reports actually demonstrating no significant difference in sleep disturbance among individuals on efavirenz compared with other cART regimens.4,56 Moreover, even among the studies reporting an association between sleep disruption and efavirenz, the findings ranged from significant changes in sleep architecture in some studies although others may have only found significant differences in reports of “unusual dream.”57,58 With the wide prevalence of efavirenz use in modern cART, future studies may consider including those undergoing treatment with efavirenz to provide further insight and generalizability. Thus, we anticipate that the findings revealed in this study will serve as additional support for conducting future and larger-scale studies to evaluate the relationship between sleep and cognition across multiple demographic groups living with HIV and undergoing varying cART regimens.
Even in the context of optimally controlled viral replication (low or undetectable viral loads), patients may still continue to experience mild or asymptomatic forms of neurocognitive dysfunction at a surprisingly high rate.59 The stringent inclusion criteria and intricate protocol employed in this study certainly biased toward the inclusion of subjects who were more stable cognitively. However, individuals demonstrating even milder forms of impairment such as ANI are at higher risk for eventual progression to more severe forms of HAND.3 Moreover, deficits sufficient to impact activities of daily living that are essential for disease management, including medication adherence, have been shown in seropositive individuals, especially those younger than 50 years, regardless of their level of cognitive impairment.60 Thus, identifying confounding factors, such as sleep disturbances that might influence the manifestation of neurocognitive impairment, is critical in the post-cART era.
The authors acknowledge Dr Adam Spira for his invaluable contributions to this project.
1. McArthur JC, Steiner J, Sacktor N, et al.. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol. 2010;67:699–714. doi:10.1002/ana.22053.
2. Wright EJ, Nunn M, Joseph J, et al.. NeuroAIDS in the Asia Pacific Region. J Neurovirol. 2008;14:465–473. doi:10.1080/13550280802235932.
3. Heaton RK, Clifford DB, Franklin DR Jr, et al.. HIV
-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75:2087–2096. doi:10.1212/WNL.0b013e318200d727.
4. Reid S, Dwyer J. Insomnia in HIV
infection: a systematic review of prevalence, correlates, and management. Psychosom Med. 2005;67:260–269. doi:10.1097/01.psy.0000151771.46127.df.
5. Ram S, Seirawan H, Kumar SK, et al.. Prevalence and impact of sleep disorders
habits in the United States. Sleep
Breath. 2010;14:63–70. doi:10.1007/s11325-009-0281-3.
6. Norman SE, Chediak AD, Freeman C, et al.. Sleep
disturbances in men with asymptomatic human immunodeficiency (HIV
) infection. Sleep
7. Norman SE, Chediak AD, Kiel M, Cohn MA. Sleep
disturbances in HIV
-infected homosexual men. AIDS. 1990;4:775–781.
8. Cruess DG, Antoni MH, Gonzalez J, et al.. Sleep
disturbance mediates the association between psychological distress and immune status among HIV
-positive men and women on combination antiretroviral therapy. J Psychosom Res. 2003;54:185–189.
9. Banks S, Dinges DF. Behavioral and physiological consequences of sleep
restriction. J Clin Sleep
10. Jones K, Harrison Y. Frontal lobe function, sleep
loss and fragmented sleep
Med Rev. 2001;5:463–475.
11. Durmer JS, Dinges DF. Neurocognitive consequences of sleep
deprivation. Semin Neurol. 2005;25:117–129.
12. Killgore WD, Balkin TJ, Wesensten NJ. Impaired decision making following 49 h of sleep
deprivation. J Sleep
13. Drummond SP, Paulus MP, Tapert SF. Effects of two nights sleep
deprivation and two nights recovery sleep
on response inhibition. J Sleep
14. Harrison Y, Jones K, Waterhouse J. The influence of time awake and circadian rhythm upon performance on a frontal lobe task. Neuropsychologia. 2007;45:1966–1972.
15. Bolla KI, Lesage SR, Gamaldo CE, et al.. Polysomnogram changes in marijuana users who report sleep
disturbances during prior abstinence. Sleep
Med. 2010;11:882–889. doi: 10.1016/j.sleep
16. Van Dongen HP, Baynard MD, Maislin G, et al.. Systematic interindividual differences in neurobehavioral impairment from sleep
loss: evidence of trait-like differential vulnerability. Sleep
17. Moyle G, Fletcher C, Brown H, et al.. Changes in sleep
quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen. HIV
18. Bastien CH, Vallieres A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep
19. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep
20. Spielberger CD, Gorsuch RL, Lushene RE. Manual for State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologist Press; 1970.
21. Krupp LB, LaRocca NG, Muir-Nash J, et al.. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–1123.
22. Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4:97–110.
23. Grossman HA, Sullivan PS, Wu AW. Quality of life
: current assessment tools and future directions for clinical practice. AIDS Read. 2003;13:583–590, 595–597.
24. Buysse DJ, Reynolds CF III, Monk TH, et al.. The pittsburgh sleep
quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213.
25. Gamaldo CE, Spira AP, Hock RS, et al.. Sleep
, function and HIV
: a multi-method assessment. AIDS Behav. 2013 [epub ahead of print].
26. Wechsler D. Wechsler Adult Intelligence Scale—Revised Manual. New York, NY: The Psycholgical Corporation; 1981.
27. Reitan RM, Wolfson D. The Halstead—Reitan Neuropsychological Test Battery. Tucson, AZ: Neuropsychology Press; 1985.
28. Brandt J, Benedict R. HVLT-R. Lutz, FL: Psychological Assessment Resources, Inc; 2001.
29. Benedict R. Brief Visuospatial Memory Test-Revised. Odessa, FL: Psychological Assessment Resources, Inc; 2006.
30. Heaton RK, PAR staff. WCST-64:CV2. Research Edition. Lutz, FL: Psychological Assessments Resources, Inc; 2000.
31. Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City, IA: University of Iowa; 1976.
32. Grooved Pegboard Test. Lafayette, IN: Lafayette Instruments; 1989.
33. Blair JR, Spreen O. Predicting premorbid IQ: a revision of the national adult reading test. Clin Neuropsychol. 1989;3:129–136.
34. Marder K, Albert SM, McDermott MP, et al.. Inter-rater reliability of a clinical staging of HIV
-associated cognitive impairment. Neurology. 2003;60:1467–1473.
35. Concha M, Selnes OA, McArthur JC, et al.. Normative data for a brief neuropsychologic test battery in a cohort of injecting drug users. Int J Addict. 1995;30:823–841.
36. Selnes OA, Jacobson L, Machado AM, et al.. Normative data for a brief neuropsychological screening battery. Multicenter AIDS Cohort Study. Percept Mot Skills. 1991;73:539–550.
37. Heaton R, Miler SW, Taylor MJ, et al.. A Professional Manual of the Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults. Lutz, FL: Psychological Assessement Resources, Inc; 2004.
38. Stewart AL, Ware JE. Measuring Function and Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1993.
39. Antinori A, Arendt G, Becker JT, et al.. Updated research nosology for HIV
-associated neurocognitive disorders. Neurology. 2007;69:1789–1799.
40. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43–46.
41. Hohagen F, Rink K, Kappler C, et al.. Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur Arch Psychiatry Clin Neurosci. 1993;242:329–336.
42. American Sleep Disorders
Association. The International Classification of Sleep Disorders
: Diagnostic and Coding Manual. Vol 2. Westchester, IL: American Academy of Sleep
43. Pearson VE, Allen RP, Dean T, et al.. Cognitive deficits associated with restless legs syndrome (RLS). Sleep
44. Darko DF, Miller JC, Gallen C, et al.. Sleep
electroencephalogram delta-frequency amplitude, night plasma levels of tumor necrosis factor alpha, and human immunodeficiency virus infection. Proc Natl Acad Sci U S A. 1995;92:12080–12084.
45. Kraft-Terry SD, Stothert AR, Buch S, et al.. HIV
-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis. 2010;37:542–548. doi:10.1016/j.nbd.2009.12.015.
46. Sevigny JJ, Albert SM, McDermott MP, et al.. Evaluation of HIV
RNA and markers of immune activation as predictors of HIV
-associated dementia. Neurology. 2004;63:2084–2090.
47. Ragin AB, Wu Y, Ochs R, et al.. Biomarkers of neurological status in HIV
infection: a 3-year study. Proteomics Clin Appl. 2010;4:295–303. doi:10.1002/prca.200900083.
48. Clinton JM, Davis CJ, Zielinski MR, et al.. Biochemical regulation of sleep
biomarkers. J Clin Sleep
Med. 2011;7(5 suppl):S38–S42. doi: 10.5664/JCSM.1360.
49. Born J, Lange T, Hansen K, et al.. Effects of sleep
and circadian rhythm on human circulating immune cells. J Immunol. 1997;158:4454–4464.
50. Mayhan WG. Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood-brain barrier. Brain Res. 2002;927:144–152.
51. Wang W, Lv S, Zhou Y, et al.. Tumor necrosis factor-alpha affects blood-brain barrier permeability in acetaminophen-induced acute liver failure. Eur J Gastroenterol Hepatol. 2011;23:552–558. doi: 10.1097/MEG.0b013e3283470212.
52. Yarlagadda A, Alfson E, Clayton AH. The blood brain barrier and the role of cytokines in neuropsychiatry. Psychiatry (Edgmont). 2009;6:18–22.
53. Centers for Disease Control and Prevention (CDC). HIV
prevalence estimates–United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57:1073–1076.
54. Jena A, Sachdeva RK, Sharma A, et al.. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care (Chic). 2009;8:318–322.
55. Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011;15:1803–1818.
56. Nguyen A, Calmy A, Delhumeau C, et al.. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS. 2011;25:57–63.
57. Rihs TA, Begley K, Smith DE, et al.. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV
58. Clifford DB, Evans S, Yang Y, et al.. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV
-infected individuals (ACTG 5097s). HIV
Clin Trials. 2009;10:343–355.
59. Simioni S, Cavassini M, Annoni JM, et al.. Cognitive dysfunction in HIV
patients despite long-standing suppression of viremia. AIDS. 2010;24:1243–1250. doi:10.1097/QAD.0b013e3283354a7b.
60. Ettenhofer ML, Hinkin CH, Castellon SA, et al.. Aging, neurocognition, and medication adherence in HIV
infection. Am J Geriatr Psychiatry. 2009;17:281–290.